Published in Drug Week, December 18th, 2009
Wei Wei, from Anhui Medical University, China, worked with a team of researchers to test the novel treatment by comparing it to the established antirheumatic drug methotrextate, in 503 RA patients. Patients who received a 12-week course of CCII capsules showed significantly improved joint function, with fewer and milder adverse effects...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.